MY163136A - Peptide radiotracer compositions - Google Patents

Peptide radiotracer compositions

Info

Publication number
MY163136A
MY163136A MYPI2013700257A MYPI2013700257A MY163136A MY 163136 A MY163136 A MY 163136A MY PI2013700257 A MYPI2013700257 A MY PI2013700257A MY PI2013700257 A MYPI2013700257 A MY PI2013700257A MY 163136 A MY163136 A MY 163136A
Authority
MY
Malaysia
Prior art keywords
compositions
imaging
vivo
binding peptides
methods
Prior art date
Application number
MYPI2013700257A
Other languages
English (en)
Inventor
Peter Brian Iveson
Rajiv Bhalla
Bard Indrevoll
Gareth Getvoldsen
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MY163136A publication Critical patent/MY163136A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
MYPI2013700257A 2010-08-18 2011-08-11 Peptide radiotracer compositions MY163136A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1013808.9A GB201013808D0 (en) 2010-08-18 2010-08-18 Peptide radiotracer compositions

Publications (1)

Publication Number Publication Date
MY163136A true MY163136A (en) 2017-08-15

Family

ID=42938098

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013700257A MY163136A (en) 2010-08-18 2011-08-11 Peptide radiotracer compositions

Country Status (19)

Country Link
US (1) US9533059B2 (enExample)
EP (1) EP2605802B1 (enExample)
JP (1) JP6014592B2 (enExample)
KR (1) KR101853993B1 (enExample)
CN (1) CN103153350B (enExample)
AU (1) AU2011290856B2 (enExample)
BR (1) BR112013003469A2 (enExample)
CA (1) CA2807491C (enExample)
CL (1) CL2013000483A1 (enExample)
ES (1) ES2626410T3 (enExample)
GB (1) GB201013808D0 (enExample)
IL (1) IL224463A (enExample)
MX (1) MX348733B (enExample)
MY (1) MY163136A (enExample)
NZ (1) NZ606466A (enExample)
PH (1) PH12013500270A1 (enExample)
RU (1) RU2594167C2 (enExample)
SG (1) SG187878A1 (enExample)
WO (1) WO2012022676A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201221266D0 (en) * 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
WO2018022603A1 (en) * 2016-07-25 2018-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
AU2020291197A1 (en) 2019-06-14 2022-01-27 Edinburgh Molecular Imaging Limited Compounds and methods of use
GB201915206D0 (en) * 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
SE2050387A1 (en) * 2020-04-06 2021-10-07 Pvac Medical Tech Ltd Labelled substance and methods of detection of inflammation and infection using said substance
TW202305012A (zh) * 2021-03-22 2023-02-01 日商肽夢想股份有限公司 c-Met 蛋白質結合肽複合物
GB202105950D0 (en) * 2021-04-26 2021-06-09 Ge Healthcare Ltd Analytical HPLC

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
AU2002357388A1 (en) 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US20050214859A1 (en) * 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
CA2656487A1 (en) 2006-07-07 2008-01-17 The Board Of Trustees Of The Leland Stanford Junior University Selective caspase inhibitors
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
US8247534B2 (en) 2006-12-13 2012-08-21 Ge Healthcare As Synthesis of radiofluorinated peptide using microwave activation technology
EP2114464A2 (en) * 2006-12-28 2009-11-11 GE Healthcare AS Radiofluorination methods
BRPI0721424A2 (pt) 2007-03-01 2014-03-25 Bayer Schering Pharma Ag Métodos de radiofluoração
RU2475266C2 (ru) 2007-05-16 2013-02-20 ДжиИ Хелткер АС Оптические агенты визуализации
GB0718957D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
GB0803477D0 (en) * 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method

Also Published As

Publication number Publication date
MX2013001939A (es) 2013-03-18
AU2011290856A1 (en) 2013-03-14
KR20130135242A (ko) 2013-12-10
RU2594167C2 (ru) 2016-08-10
BR112013003469A2 (pt) 2016-06-21
MX348733B (es) 2017-06-27
JP2013540702A (ja) 2013-11-07
CA2807491C (en) 2019-06-04
AU2011290856B2 (en) 2014-12-04
NZ606466A (en) 2014-11-28
GB201013808D0 (en) 2010-09-29
CN103153350A (zh) 2013-06-12
KR101853993B1 (ko) 2018-05-02
WO2012022676A1 (en) 2012-02-23
US9533059B2 (en) 2017-01-03
SG187878A1 (en) 2013-03-28
EP2605802B1 (en) 2017-04-26
EP2605802A1 (en) 2013-06-26
US20130149241A1 (en) 2013-06-13
JP6014592B2 (ja) 2016-10-25
CN103153350B (zh) 2016-06-29
RU2013105491A (ru) 2014-09-27
ES2626410T3 (es) 2017-07-25
CA2807491A1 (en) 2012-02-23
IL224463A (en) 2016-05-31
PH12013500270A1 (en) 2013-04-01
CL2013000483A1 (es) 2014-03-07

Similar Documents

Publication Publication Date Title
MY163136A (en) Peptide radiotracer compositions
MX2013010012A (es) Analogos de octreotato radiomarcado como trazadores de tomografia por emision de positrones.
MY150757A (en) Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
MX2011010295A (es) Reactivos de radiomarcado y metodos.
ECSP11010808A (es) Daa-piridina como ligando del receptor periférico de benzodiazepina para el diagnóstico por imágenes y para el tratamiento farmacéutico
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
EA201290712A1 (ru) Альфа-излучающие комплексы
MY188934A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
GB201103696D0 (en) Technetium labelled peptides
EP2928505A4 (en) POSITRONARY EMITTING RADIONUCLEID MARKED PEPTIDES FOR HUMAN UPAR PET IMAGING
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
WO2009134405A3 (en) Substrate based pet imaging agents
WO2009025914A3 (en) Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging
WO2009018175A3 (en) Cyclic azapeptides as integrin markers
Aranda-Lara et al. Improved radiopharmaceutical based on 99mTc-Bombesin–folate for breast tumour imaging
GB201121914D0 (en) Method for patient selection
MX2013003398A (es) Agentes de generacion de imagen de apoptosis con base en peptidos lantibioticos.
WO2012040138A3 (en) Choline analogs as radiotracer
WO2011084585A3 (en) Dihydroethidine analogues and uses thereof
WO2012040133A3 (en) Novel precursors of radiolabelled choline analog compounds
WO2009111273A3 (en) Peptide targeting imaging agents and methods of use thereof
MX340407B (es) Simplificacion de proceso para compuesto precursor.
GB0421987D0 (en) Novel technetium and rhenium complexes
GB201205703D0 (en) Synthon composition
Juweid et al. Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?